Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ACRV

Acrivon Therapeutics

ACRV Rare disease Lead: Phase 2 15 Biotech Distilled articles ↓ 26 filings & releases ↓ Cash $41.4M (Jun 30, 2026) ↓ 15 verdicts ↓ 1 timing quote ↓
GI/HepatologyOncology Small Molecule

Market cap $69.0M 42.9M shares (10-Q, Aug 7, 2026) × $1.61 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. ACR-368 Phase 2b EC Ph2b2H 2026ACR-368 Phase 2b EC Ph2b, 2H 2026, material
  2. CDK11 program IND filing1H 2027CDK11 program IND filing, 1H 2027, notable
  3. ACR-6840 corporate update1H 2027ACR-6840 corporate update, 1H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Technology platforms

AP3

Generative Phosphoproteomics Acrivon Predictive Precision Proteomics platform — quantifies compound-specific, drug-regulated pathway activity levels inside the intact cell via MS-based proteomic profiling and automated tumor imaging biomarker platform; applied to oncology drug discovery, patient selection (OncoSignature tests), indication finding, and resistance mechanism identification

Targets: CDK1, CDK2, PLK1, CHK1, CHK2, WEE1, PKMYT1, CDK11

Capital (as filed)

Cash
$41.4M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$48.5M Jun 30, 2026
Operating cash flow
−$14.9M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$90.0M cash, runway fourth quarter of 2027 per the update of Aug 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (15)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (15 calls)

Every verdict Biotech Distilled has published on Acrivon Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-01-05 Watch Acrivon Therapeutics (ACRV): Scientific Deep Dive for ACR-2316 and ACR-368 Science is real but the January 2026 ACR-2316 safety data is the single most important data point; wait for a clean safety profile before entering.
  2. 2026-01-08 Buy core ACRV UPDATE: Platform Supported. Acrivon (ACRV) Clears the Bar. ACR-368 achieved 39% ORR in biomarker-positive patients and ACR-2316 showed confirmed responses with manageable safety, validating the AP3 platform and de-risking the one-drug pony fear.
  3. 2026-01-10 Speculative buy speculative UPDATE: Acrivon (ACRV) Granular Review: Did the Market Just Throw the Baby Out with the Bathwater? The ~50% post-data crash appears to be an overreaction to a solvable dosing schedule problem; the 2-on/5-off schedule shows a manageable 17% Grade 3/4 neutropenia rate, making this a speculative buy at current levels.
  4. 2026-01-17 Buy core Insider Alert: Acrivon (ACRV) - Executives Are Eating Their Own Cooking. CEO and CFO open-market purchases at ~$1.68-1.70 after the 50% crash support the overreaction hypothesis and signal management confidence in the 2-on/5-off dosing solution.
  5. 2026-01-25 Buy core Update: Acrivon (ACRV) - Catalyst Added: ACRV Takes the Main Stage in Europe. Late-breaking oral acceptance at ESGO provides an external quality stamp on the ACR-368 data and keeps momentum alive while the company optimizes ACR-2316 dosing.
  6. 2026-02-21 Buy core UPDATE: Acrivon (ACRV) Brings Its Moat In-House. CLIA certification for a wholly-owned diagnostic lab gives Acrivon full control over its OncoSignature IP and makes it a more attractive partner for Big Pharma.
  7. 2026-02-28 Buy core UPDATE: Acrivon (ACRV) - The Late-Breaking Letdown and the Anatomy of a Friday Flush. The ESGO sell-the-news reaction was driven by momentum traders disappointed by no new data, not by any change in the underlying thesis; the drug works exactly as well as it did on January 8th.
  8. 2026-03-07 Buy core UPDATE: Acrivon (ACRV) - Officially Cuts the Cord with its Diagnostic Vendor Clean termination of the Akoya/Quanterix diagnostic agreement with no financial penalty consolidates full commercial rights to the OncoSignature test and de-risks future partnerships.
  9. 2026-03-21 Buy core UPDATE: Acrivon (ACRV) - The Partnership Pitch Takes Shape Ahead of AACR Upcoming AACR data showing synergy with Topo 1 ADCs and IO agents frames Acrivon as a prime partnership target for Big Pharma's most lucrative oncology franchises.
  10. 2026-04-27 Buy core UPDATE: Acrivon (ACRV) - RA Capital Just Backstopped the ATM at $1.80 RA Capital adding 3.9M shares at $1.80 via a clean ATM with no warrants or discount is the strongest institutional signal since the CEO's January open-market buy, and the dilution gap is being managed at-market.
  11. 2026-05-13 Buy core UPDATE: Acrivon (ACRV) - The 2H 2026 Catalyst Just Got Locked In A prespecified simultaneous interim on both serous all-comer arms in 2H 2026 concentrates the next major catalyst into a defined window, and runway is confirmed into Q3 2027 past that event.
  12. 2026-08-06 Buy core UPDATE: Acrivon (ACRV) - The Dosing Problem That Crashed the Stock Just Got Solved ACR-2316 moves into randomized dose expansion at 120/160 mg on 3-on/4-off with no grade ≥4 TRAEs and three heavily pretreated lung cancer patients past one year on drug, substantially retiring the January tolerability risk.
  13. 2026-08-13 Buy core UPDATE: Acrivon (ACRV) - The Phase 3 Now Has a Date, and the Runway Reaches It Runway extended to Q4 2027 through expense discipline without a raise, and the confirmatory Phase 3 is now dated to 1H 2027, pushing the large-raise conversation past the 2H 2026 interim.
  14. 2026-10-30 Buy core UPDATE: Acrivon (ACRV) - The Crown Jewel Posts Its First Complete Response A confirmed complete response (including PET) in fourth-line squamous NSCLC on ACR-2316, plus durable lung responses past one year, is the hardest kind of durability evidence and validates the AP3 platform prospectively.
  15. 2026-11-07 Hold UPDATE: Acrivon (ACRV) - The Oncology Company Just Bought an Autoimmune Drug Acquiring a JAK1 inhibitor for undisclosed cash weeks before the binary serous interim widens the dilution gap and splits management attention, warranting a downgrade to hold until the purchase price and EoE Phase 2 cost are disclosed or the interim reads out.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 17, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)